|
| Press Releases |
|
 |
|
| Friday, August 30, 2024 |
|
|
Hua Medicine Announces 2024 Interim Results |
| Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2024 (the "Reporting Period"), and the Company's business progress for the first half of the year and business outlook. more info >> |
|
| Friday, August 25, 2023 |
|
|
Hua Medicine Announces 2023 Interim Results |
| First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. more info >> |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Aleen Inc. Introduces Biomarker Data Layer in Personal Wellness Account
Mar 25, 2026 23:28 HKT/SGT
|
|
|
Hengrui Pharma Announces Strong 2025 Annual Results
Mar 25, 2026 23:15 HKT/SGT
|
|
|
Everbright Grand China Assets Recorded Revenue of RMB49.9 Million in 2025
Mar 25, 2026 22:39 HKT/SGT
|
|
|
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia
Mar 25, 2026 20:30 HKT/SGT
|
|
|
Adyton Reports 6.60g/t Au, 2.44% Cu and 39.8g/t Ag Within 164m @ 0.82g/t AuEq Including 53m at 1.60g/t AuEq Within 164m at 0.82g/t AuEq from the Northeastern Extension Target, Feni Island
Mar 25, 2026 19:29 HKT/SGT
|
|
|
Emperor Watch & Jewellery Limited Announces 2025 Annual Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
Kingsoft announces 2025 Annual and Fourth Quarter Results
Mar 25, 2026 18:06 HKT/SGT
|
|
|
New 2026 Office Bearers Announced for CropLife Asia
Mar 25, 2026 18:00 HKT/SGT
|
|
|
IGG 'Doomsday: Last Survivors' Achieves Record-High Monthly Gross Billing of HK$130 Million
Mar 25, 2026 17:40 HKT/SGT
|
|
|
Exito Media Concepts Announces the 31st Global Edition of the Cyber Security Summit Australia 2026 
Mar 25, 2026 17:18 HKT/SGT
|
|
|
Exito Media Concepts Announces the 33rd Global Edition of the BFSI IT Summit Australia 2026
Mar 25, 2026 16:58 HKT/SGT
|
|
|
GTJAI (1788.HK) Achieved Record-High Revenue in 2025 with Profitability Making a Leapfrog Improvement
Mar 25, 2026 16:44 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 25, 2026 16:34 HKT/SGT
|
|
|
Thailand Exhibition Association Unveils Transformative MICE Masterplan 2026-2027
Mar 25, 2026 16:26 HKT/SGT
|
|
|
Sumitomo Heavy Industries and NEC to develop system capable of identifying and reporting near-miss incidents
Mar 25, 2026 14:27 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
